Orna Therapeutics

Executive Summary

Orna Therapeutics is pioneering a novel circular RNA (oRNA) platform designed to overcome key limitations of linear mRNA therapeutics. By engineering stable, self-circularizing RNA molecules, the company enables prolonged and higher-level protein expression, which is critical for applications ranging from cancer immunotherapy to infectious disease vaccines. Founded in 2019 and headquartered in Cambridge, MA, Orna has raised over $220 million from top-tier investors, reflecting strong confidence in its technology. The company is advancing a pipeline of wholly owned and partnered programs, with a focus on in vivo cell engineering—particularly for CAR-T therapy and other oncology targets—as well as prophylactic and therapeutic vaccines. Although still preclinical, Orna’s platform has demonstrated compelling proof-of-concept in animal models, positioning it as a potential leader in next-generation RNA therapeutics. Orna’s differentiated approach addresses the inherent instability and immunogenicity of linear mRNA, offering advantages in durability, potency, and manufacturing. The oRNA platform is also designed to be modular, enabling rapid development of new candidates. The company is currently progressing its lead oncology program toward IND-enabling studies and expects to initiate its first clinical trial in 2027. Partnerships with major pharmaceutical companies further validate the platform’s potential. With a robust intellectual property estate and a seasoned management team, Orna is well-positioned to translate its technology into transformative medicines. Near-term milestones include selection of development candidates, completion of IND-enabling toxicology, and potential business development deals.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead In Vivo CAR-T Program60% success
• Q4 2026Announcement of Major Partnership or License Deal55% success
• Q3 2026Publication of Preclinical Proof-of-Concept Data for mRNA Vaccine Candidate70% success